Affinia Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for AFTX-201, a gene therapy for the treatment of dilated cardiomyopathy (DCM) associated with a mutation in the BAG3 gene.[1] AFTX-201 delivers a fully human, complete BAG3 transgene using Affinie's proprietary capsid, which enables efficient cardiac transduction at doses 5-10-fold lower than conventional capsids such as AAV9 or AAVrh74.[1][2] It is given as a single intravenous injection.[1][2] Preclinical studies in an animal model have shown that AFTX-201 increases BAG3 protein levels in the heart and fully restores cardiac function.[1][2] Safety and efficacy are being investigated in the UPBEAT clinical trial, which includes a dose-expansion and dose-expansion phase.[1] All participants will receive a single intravenous infusion of AFTX-201 at a dose deemed safe and effective based on preclinical studies.[1][2] The primary objective of the study is to assess safety and tolerability for 52 weeks after administration, with additional objectives for pharmacodynamics and preliminary efficacy.[1][2] Fast-track FDA designation allows for more frequent interactions with the agency and accelerated drug development for serious conditions with unmet need.[1]